AI Article Synopsis
- Alzheimer's disease (AD) is a major cause of dementia, with no current therapies that modify the disease progression.
- Researchers tested a vaccine called Aβ3-10-KLH on young genetically modified mice to see if it can reduce amyloid-β levels after these have already formed.
- The results showed that the vaccine not only lowered amyloid-β deposits but also enhanced cognitive abilities and helped fix mitochondrial issues, suggesting it could be a promising treatment for AD.
Article Abstract
Alzheimer's disease is a common cause of dementia, for which no disease-modifying therapy is yet available. Aβ3-10-KLH, a vaccine for active immunization, has been shown to prevent pathological changes in young transgenic models of AD, but the effects of treatment with it and its effects on mitochondrial dysfunction remain unclear. We immunized 6-month-old Tg-APPswe/PSEN1dE9 mice with Aβ3-10-KLH to analyze whether it is capable of eliminating amyloid-β after its appearance. The vaccine effectively decreased amyloid-β deposits, improved cognitive function and ameliorated mitochondrial dysfunction. These results indicate the potential of Aβ3-10-KLH as a vaccine to treat AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.brainresbull.2021.05.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!